<DOC>
	<DOCNO>NCT03048006</DOCNO>
	<brief_summary>Guerbet conduct non-interventional post-marketing surveillance study Magnetic Resonance Imaging ( MRI ) contrast agent Dotarem ( gadoteric acid/gadoterate meglumine ) . The aim study , conduct accordance section 67 , paragraph 6 German drug regulation , Arzneimittelgesetz , gain additional insight diagnostic efficacy , reliability safety Dotarem routine practice use up-to-date MRI technique application method .</brief_summary>
	<brief_title>Post-marketing Surveillance Study Evaluation Dotarem Safety</brief_title>
	<detailed_description>Diagnostic efficacy assess follow endpoint : diagnostic value ( `` yes '' / '' '' ) image quality ( 5-step scale `` excellent '' `` poor '' ) . Safety evaluate basis frequency seriousness adverse event occur follow Dotarem injection .</detailed_description>
	<criteria>Patients undergo routine MRI use MRI contrast medium Dotarem</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>